Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutations in urothelial carcinoma: not all one and the same†.

The Journal of pathology - 1 Oct 2024

Barr Alexis R, Burley Amy, Wilkins Anna

Abstract excerpt

Systemic therapy options for urothelial carcinoma have expanded in recent years, with both immunotherapy and cytotoxic chemotherapy being widely available. However, we lack biomarkers to select which drug is likely to work best in individual patients. A new article in this journal by Jin, Xu, Su, et al reports that disruptive versus non-disruptive TP53 mutations may guide these personalised therapy choices....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Transitional Cell
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Tumor Microenvironment

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Share to Urothelium

Source

Identifiers

PMID: 39046056
DOI: 10.1002/path.6335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations in urothelial carcinoma: not all one and the same†.PMID 39046056Read ↗

TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.Semantic proximity Read ↗

Molecular classification and diagnostics of upper urinary tract urothelial carcinoma.Semantic proximity Read ↗

Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing.Semantic proximity Read ↗

Similar genetic profile in early and late stage urothelial tract cancer.Semantic proximity Read ↗

Molecular Pathology of Urothelial Carcinoma.Semantic proximity Read ↗

Mutational Landscape of TP53 Across Cancer TypesSemantic proximity Read ↗

Beyond driver mutations: exploring the landscape of mutational signatures in adenocarcinomas of the bladder†.Semantic proximity Read ↗

A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.Semantic proximity Read ↗

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.Semantic proximity Read ↗

Effect of co-occurring mutations in TP53 gene and TERT promoter on the survival of bladder cancer patients.Semantic proximity Read ↗

Mutations in TP53 and other heterogeneous genes help to distinguish metastases from new primary malignanciesSemantic proximity Read ↗

Mutational signature and prognosis in adenocarcinoma of the bladder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.